References
1. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Seminars in nephrology. 2004;24(3):179-96.
2. Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. Journal of nephrology. 2017;30(3):339-46.
3. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. The American journal of medicine. 1990;89(2):209-15.
4. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney international. 2012;81(9):833-43.
5. Lai KN. Pathogenesis of IgA nephropathy. Nature reviews Nephrology. 2012;8(5):275-83.
6. Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney international. 2015;88(5):974-89.
7. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F et al. The pathophysiology of IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2011;22(10):1795-803.
8. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nature reviews Immunology. 2012;12(3):191-200.
9. Mellis SJ, Baenziger JU. Structures of the O-glycosidically linked oligosaccharides of human IgD. The Journal of biological chemistry. 1983;258(19):11557-63.
10. Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgD in IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2006;17(4):1192-9.
11. Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ. IgA nephropathy. Nature reviews Disease primers. 2016;2:16001.
12. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. The Journal of clinical investigation. 2014;124(6):2325-32.
13. Vossenkamper A, Blair PA, Safinia N, Fraser LD, Das L, Sanders TJ, Stagg AJ, Sanderson JD et al. A role for gut-associated lymphoid tissue in shaping the human B cell repertoire. The Journal of experimental medicine. 2013;210(9):1665-74.
14. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatric nephrology (Berlin, Germany). 2018;33(5):763-77.
15. Buren M, Yamashita M, Suzuki Y, Tomino Y, Emancipator SN. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contributions to nephrology. 2007;157:50-5.
16. Harper SJ, Pringle JH, Wicks AC, Hattersley J, Layward L, Allen A, Gillies A, Lauder I. et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney international. 1994;45(3):836-44.
17. Esteve Cols C, Graterol Torres FA, Quirant Sanchez B, Marco Rusinol H, Navarro Diaz MI, Ara Del Rey J, Martinez Caceres EM. Immunological Pattern in IgA Nephropathy. International journal of molecular sciences. 2020;21(4).
18. Si R, Zhao P, Yu Z, Qu Z, Sun W, Li T, Jiang Y. Increased Non-switched Memory B Cells are Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN Patients. Immunological investigations. 2019:1-13.
19. Arumugakani G, Stephenson SJ, Newton DJ, Rawstron A, Emery P, Doody GM, McGonagle D, Tooze RM. Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. Journal of immunology (Baltimore, Md : 1950). 2017;198(12):4618-28.
20. Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nature reviews Nephrology. 2016;12(4):232-40.
21. Landsverk OJ, Snir O, Casado RB, Richter L, Mold JE, Reu P, Horneland R, Paulsen V. et al. Antibody-secreting plasma cells persist for decades in human intestine. The Journal of experimental medicine. 2017;214(2):309-17.
22. Huang JL, Woolf AS, Kolatsi-Joannou M, Baluk P, Sandford RN, Peters DJ, McDonald DM, Price KL. et al. Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases. Journal of the American Society of Nephrology : JASN. 2016;27(1):69-77.
23. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Frontiers in immunology. 2013;4:23.
24. Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT. Phenotypic characterization of human intermediate monocytes. Frontiers in immunology. 2013;4:339.
25. Cox SN, Serino G, Sallustio F, Blasi A, Rossini M, Pesce F, Schena FP. Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30(7):1122-232.
26. Wallquist C, Paulson JM, Hylander B, Lundahl J, Jacobson SH. Increased accumulation of CD16+ monocytes at local sites of inflammation in patients with chronic kidney disease. Scandinavian journal of immunology. 2013;78(6):538-44.
27. Zhu H, Hu F, Sun X, Zhang X, Zhu L, Liu X, Li X, Xu L. et al. CD16(+) Monocyte Subset Was Enriched and Functionally Exacerbated in Driving T-Cell Activation and B-Cell Response in Systemic Lupus Erythematosus. Frontiers in immunology. 2016;7:512.
28. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clinical and experimental immunology. 1999;117(1):153-8.
29. van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, Blanchard D. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. European journal of immunology. 1994;24(4):787-92.
30. Bjorck P, Braesch-Andersen S, Paulie S. Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. Immunology. 1994;83(3):430-7.
Figure legends
Figure. 1 Gating strategies for analysis of CD3- CD19+ CD27- IgD+ naïve B cells, CD3- CD19+ CD27+ IgD+ pre-switched B cells, CD3- CD19+ CD27+ IgD- switched B cells, CD3- CD19- CD27 hiCD38 hi long-lived plasma cells and monocyte subsets.
Figure 2. Proportions of B cell subsets in patients with IgA nephropathy (IgAN), autosomal dominant polycystic kidney disease (ADPKD) and in healthy controls (HC). Comparisons for cell fractions were performed using the Kruskal-Wallis test, P < 0.05 was considered statistically significant. Scatter plots represent the range with whiskers and the median as the middle line.
Figure 3. Ratio of naïve/pre-switched B cells in patients with IgA nephropathy (IgAN), autosomal dominant polycystic kidney disease (ADPKD) and healthy controls (HC). Comparisons for cell fractions were performed using the Kruskal-Wallis test, P < 0.05 was considered statistically significant. Scatter plots represent the range with whiskers and the median as the middle line.
Figure 4. Proportions of non-classical monocytes in patients with IgAN, ADPKD and HC. Comparisons for cell fractions were performed using the Kruskal-Wallis test, P < 0.05 was considered statistically significant. Scatter plots represent the range with whiskers and the median as the middle line.
Figure 5. Levels of cytokines in plasma from IgAN patients and healthy controls. Mann-Whitney U test was used to compare cytokine concentrations, P < 0.05 was considered statistically significant. Scatter plots represent the range with whiskers and the median as the middle line.
Figure 6. The relationship between MCP-1 / sCD40L levels and albuminuria in IgAN patients using linear regression test.
Figure 7. The relationship between cytokines and immune cell subtypes in IgAN patients using linear regression test.
Table 1 Demographic characteristics of study subjects.